Rishabh Sharma, Jasdeep Kaur Gill, Caitlin Carter, Wajd Alkabbani, Manik Chhabra, Kota Vidyasagar, Feng Chang, Linda Lee, Tejal Patel
{"title":"在记忆门诊就诊的痴呆症或认知障碍老年人中使用潜在不当药物的情况:系统回顾与元分析协议》。","authors":"Rishabh Sharma, Jasdeep Kaur Gill, Caitlin Carter, Wajd Alkabbani, Manik Chhabra, Kota Vidyasagar, Feng Chang, Linda Lee, Tejal Patel","doi":"10.1159/000539074","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Older adults with dementia who are on multiple medications are more vulnerable to the use of potentially inappropriate medications (PIMs), which can significantly increase the risk of adverse events and drug-related problems. PIMs use is prevalent and varies among older adults with dementia or cognitive impairment (CI) attending memory clinics. However, the prevalence of PIMs, polypharmacy, and hyper-polypharmacy among older adults with dementia or CI who are attending memory clinics is not well understood. We will conduct a systematic review and meta-analyses to examine the overall estimate of the prevalence of the PIMs, polypharmacy, and hyper-polypharmacy use among older adults attending memory clinics, with dementia or CI. The secondary objective of this study will be to compile a list of commonly implicated PIMs and to investigate factors that may be associated with using PIMs in this population.</p><p><strong>Methods: </strong>Ovid MEDLINE, Ovid Embase, Scopus, Cochrane library, EBSCOhost CINAHL, and Ovid International Pharmaceutical Abstracts (IPA) will be systematically searched by a researcher (R.S.) with the help of a librarian (C.C.). All databases will be searched from inception to May 05, 2023. Cross-sectional, cohort, randomized clinical trials, quasi-experimental, and case-control studies will be included if they assess PIM's use among older adults with dementia and/or CI. A step-by-step guide by Pai et al. [Natl Med J India. 2004;17(2):86-95] will be followed when conducting this systematic review (S.R.). The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist will be followed for reporting this SR.</p><p><strong>Conclusion: </strong>The findings from this SR/MA will identify the pooled prevalence of PIMs, providing a more precise estimate of the true prevalence of the PIMs, polypharmacy, hyper-polypharmacy in older adults with dementia or CI who are attending memory clinics at primary, secondary, or tertiary healthcare settings by considering the results of multiple studies.</p>","PeriodicalId":101351,"journal":{"name":"Biomedicine hub","volume":"9 1","pages":"83-88"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249799/pdf/","citationCount":"0","resultStr":"{\"title\":\"Use of Potentially Inappropriate Medications among Older Adults with Dementia or Cognitive Impairment Attending Memory Clinics: A Protocol for a Systematic Review and Meta-Analysis.\",\"authors\":\"Rishabh Sharma, Jasdeep Kaur Gill, Caitlin Carter, Wajd Alkabbani, Manik Chhabra, Kota Vidyasagar, Feng Chang, Linda Lee, Tejal Patel\",\"doi\":\"10.1159/000539074\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Older adults with dementia who are on multiple medications are more vulnerable to the use of potentially inappropriate medications (PIMs), which can significantly increase the risk of adverse events and drug-related problems. PIMs use is prevalent and varies among older adults with dementia or cognitive impairment (CI) attending memory clinics. However, the prevalence of PIMs, polypharmacy, and hyper-polypharmacy among older adults with dementia or CI who are attending memory clinics is not well understood. We will conduct a systematic review and meta-analyses to examine the overall estimate of the prevalence of the PIMs, polypharmacy, and hyper-polypharmacy use among older adults attending memory clinics, with dementia or CI. The secondary objective of this study will be to compile a list of commonly implicated PIMs and to investigate factors that may be associated with using PIMs in this population.</p><p><strong>Methods: </strong>Ovid MEDLINE, Ovid Embase, Scopus, Cochrane library, EBSCOhost CINAHL, and Ovid International Pharmaceutical Abstracts (IPA) will be systematically searched by a researcher (R.S.) with the help of a librarian (C.C.). All databases will be searched from inception to May 05, 2023. Cross-sectional, cohort, randomized clinical trials, quasi-experimental, and case-control studies will be included if they assess PIM's use among older adults with dementia and/or CI. A step-by-step guide by Pai et al. [Natl Med J India. 2004;17(2):86-95] will be followed when conducting this systematic review (S.R.). The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist will be followed for reporting this SR.</p><p><strong>Conclusion: </strong>The findings from this SR/MA will identify the pooled prevalence of PIMs, providing a more precise estimate of the true prevalence of the PIMs, polypharmacy, hyper-polypharmacy in older adults with dementia or CI who are attending memory clinics at primary, secondary, or tertiary healthcare settings by considering the results of multiple studies.</p>\",\"PeriodicalId\":101351,\"journal\":{\"name\":\"Biomedicine hub\",\"volume\":\"9 1\",\"pages\":\"83-88\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249799/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicine hub\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000539074\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine hub","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:服用多种药物的老年痴呆症患者更容易使用潜在的不适当药物(PIMs),这会大大增加不良事件和药物相关问题的风险。在前往记忆门诊就诊的患有痴呆症或认知障碍(CI)的老年人中,PIMs 的使用非常普遍,而且情况各不相同。然而,在记忆门诊就诊的痴呆症或认知障碍老年人中,PIMs、多药联用和超多药联用的发生率并不十分清楚。我们将开展一项系统性综述和荟萃分析,研究记忆门诊就诊的老年痴呆症或 CI 患者中 PIMs、多药联用和过度多药联用发生率的总体估计值。本研究的次要目标是编制一份常见PIMs清单,并调查可能与该人群使用PIMs有关的因素:研究人员(R.S.)将在图书管理员(C.C.)的帮助下系统地检索 Ovid MEDLINE、Ovid Embase、Scopus、Cochrane 图书馆、EBSCOhost CINAHL 和 Ovid International Pharmaceutical Abstracts (IPA)。所有数据库的检索时间从开始到 2023 年 5 月 5 日。如果横断面研究、队列研究、随机临床试验、准实验研究和病例对照研究对患有痴呆症和/或 CI 的老年人使用 PIM 的情况进行了评估,则将纳入这些研究。在进行本系统综述时,将遵循 Pai 等人的逐步指南[Natl Med J India.在报告本系统综述时,将遵循 PRISMA(系统综述和元分析首选报告项目)清单:本 SR/MA 的研究结果将确定 PIMs 的总体流行率,通过考虑多项研究的结果,更精确地估计在初级、二级或三级医疗机构记忆门诊就诊的老年痴呆症或 CI 患者中 PIMs、多重药物治疗、多重药物治疗过度的真实流行率。
Use of Potentially Inappropriate Medications among Older Adults with Dementia or Cognitive Impairment Attending Memory Clinics: A Protocol for a Systematic Review and Meta-Analysis.
Introduction: Older adults with dementia who are on multiple medications are more vulnerable to the use of potentially inappropriate medications (PIMs), which can significantly increase the risk of adverse events and drug-related problems. PIMs use is prevalent and varies among older adults with dementia or cognitive impairment (CI) attending memory clinics. However, the prevalence of PIMs, polypharmacy, and hyper-polypharmacy among older adults with dementia or CI who are attending memory clinics is not well understood. We will conduct a systematic review and meta-analyses to examine the overall estimate of the prevalence of the PIMs, polypharmacy, and hyper-polypharmacy use among older adults attending memory clinics, with dementia or CI. The secondary objective of this study will be to compile a list of commonly implicated PIMs and to investigate factors that may be associated with using PIMs in this population.
Methods: Ovid MEDLINE, Ovid Embase, Scopus, Cochrane library, EBSCOhost CINAHL, and Ovid International Pharmaceutical Abstracts (IPA) will be systematically searched by a researcher (R.S.) with the help of a librarian (C.C.). All databases will be searched from inception to May 05, 2023. Cross-sectional, cohort, randomized clinical trials, quasi-experimental, and case-control studies will be included if they assess PIM's use among older adults with dementia and/or CI. A step-by-step guide by Pai et al. [Natl Med J India. 2004;17(2):86-95] will be followed when conducting this systematic review (S.R.). The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist will be followed for reporting this SR.
Conclusion: The findings from this SR/MA will identify the pooled prevalence of PIMs, providing a more precise estimate of the true prevalence of the PIMs, polypharmacy, hyper-polypharmacy in older adults with dementia or CI who are attending memory clinics at primary, secondary, or tertiary healthcare settings by considering the results of multiple studies.